Who Paid My Doc
Rebecca Elbert
Clinical Nurse Specialist Fargo, ND Clinical Nurse Specialist
NPI 1235156191 CMS profile 1053126
3220 4Th St E Ste 102, Fargo, ND 58104
General payments
$260
Research payments
$0
Ownership & investment interest
$0
Through program year 2023, Rebecca Elbert of Fargo, ND is reported in the CMS Open Payments database as having received $260 across 13 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 49th percentile of Clinical Nurse Specialist profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | General | $84 | 3 | |
| 2022 | General | $176 | 10 |
Beside peers
- Rebecca Elbert
- Clinical Nurse Specialist median
- Middle half of Clinical Nurse Specialist
- National median
In program year 2025, general payments to Rebecca Elbert were reported at $0. Among 490 Clinical Nurse Specialist profiles paid that year, the median was $149 and the middle half received between $61 and $470.
Show as a table
| Year | Rebecca Elbert | Clinical Nurse Specialist median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | — | — | $163 |
| 2020 | $0 | — | — | $114 |
| 2021 | $0 | $132 | $42–$386 | $132 |
| 2022 | $176 | $140 | $55–$364 | $149 |
| 2023 | $84 | $145 | $50–$403 | $160 |
| 2024 | $0 | $145 | $55–$430 | $164 |
| 2025 | $0 | $149 | $61–$470 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 12 drugsPart D claims
207
Drug cost
$6,184
Branded share of claims
31.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Vilazodone Hcl | Generic | 24 | $2,396 | |
| Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine | Brand | 30 | $797 | |
| Duloxetine Hcl | Generic | 12 | $572 | |
| Lamotrigine | Generic | 22 | $525 | |
| Ziprasidone Hcl | Generic | 15 | $483 | |
| Bupropion Xl Bupropion Hcl | Brand | 24 | $447 | |
| Aripiprazole | Generic | 14 | $300 | |
| Quetiapine Fumarate | Generic | 12 | $266 | |
| Zolpidem Tartrate | Generic | 17 | $130 | |
| Escitalopram Oxalate | Generic | 15 | $112 |
The 10 drugs with the highest cost, of 12 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,644 Part D prescribers listed as Certified Clinical Nurse Specialist; they describe a distribution and say nothing about conduct.
Records
13 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Clinical Nurse Specialist in North Dakota
Related records
Clinical Nurse Specialist in North Dakota
Practitioners in the same specialty and state, ranked by reported value.
All Clinical Nurse Specialist
Everyone recorded under this specialty, nationwide.
Doctors in North Dakota
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.